Mikhail Blagosklonny is a renowned scientist whose studies focus on cancer and ageing. He is a professor of Oncology at the Roswell Park Cancer Institute. He got his MD in internal medicine and PHD in Experimental Medicine and Cardiology from the First Pavlov State Medical University, St Petersburg. Mikhail Blagosklonny was chosen to serve as an associate professor of medicine at the New York Medical College Valhalla in 2002 before accepting a position of Senior Scientist at Ordway Research Institute.
Blagosklonny served as a senior scientist until 2009 when he was appointed Professor of Oncology at Roswell Park Cancer Institute. He focuses on cancer therapies that protect healthy cells from damage and also key mechanisms of ageing and anti-aging drugs.
He has published over 270 papers journals such as TOR- centric view of insulin resistance and diabetic complications perspective for endocrinologists and gerontologist where he talks about endocrinologist treating patients with diabetic complications as well as basic scientists studying an elusive link between ageing and the disease. The article answers questions like what is there between insulin resistance cellular ageing and diseases, why complications like retinopathy may paradoxically precede the onset of diabetic types, among other issues. This and many other articles have led him to get an h-index.
At Roswell Park Cancer Centre, Mikhail is the editor in chief. He is also associated with cancer Biology and treatment and a member of the editorial board of Cell Death and Differentiation. Mikhail Blagosklonny has formed a hypothesis about the possible roles of Target of Rapamycin signaling in ageing and cancer and advocated for the utilization of rapamycin which is a popular cancer drug to extend life. He is said to be one of the most passionate advocates for rapamycin in lengthening life. Mikhail improves humanity through oncology. Read more about Mikhail at LinkedIn.com